American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 79-90 , January 2009

Associates of Mortality and Hospitalization in Hemodialysis: Potentially Actionable Laboratory Variables and Vascular Access

Received 20 November 2007 ,Accepted 29 July 2008.

References 

  1. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  2. Lacson E, Teng M, Lazarus JM, Lew N, Lowrie E, Owen W. Limitations of the facility-specific standardized mortality ratio for profiling health care quality in dialysis. Am J Kidney Dis. 2001;37:267–275
  3. Lowrie EG, Teng M, Lacson E, Lew N, Lazarus JM, Owen WF. Association between prevalent care process measures and facility-specific mortality rates. Kidney Int. 2001;60:1917–1929
  4. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  5. Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodialysis Int. 2005;9:367–375
  6. Li Z, Lacson E, Lowrie EG, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis. 2006;48:606–615
  7. Lowrie EG, Li Z, Ofsthun NJ, Lazarus JM. Evaluating a new method to judge dialysis treatment using online measurements of ionic clearance. Kidney Int. 2006;70:211–217
  8. Mishler R, Sands JJ, Ofsthun NJ, Teng M, Schon D, Lazarus JM. Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments. Kidney Int. 2006;69:393–398
  9. Williams ME, Lacson E, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006;70:1503–1509
  10. Lowrie EG, Zhu X, Lew NL. Primary associates of mortality among dialysis patients: Trends and reassessment of Kt/V and urea reduction ratio as outcome-based measures of dialysis dose. Am J Kidney Dis. 1998;32(suppl 4):S16–S31
  11. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis. 1998;31:997–1006
  12. Lowrie EG, Huang W, Lew NL, Liu Y. The relative contribution of measured variables to death risk among hemodialysis patients. In:  Friedman E editors. Death on Hemodialysis: Preventable or Inevitable?. Hingham, MA: Kluwer Academic Publishers; 1994;p. 121–141
  13. Smye SW, Tattersall JE, Will EJ. Modeling the postdialysis rebound: The reconciliation of current formulas. ASAIO J. 1999;45:562–567
  14. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2006. Am J Kidney Dis. 2006;48(suppl 1):S2–S90
  15. Pankratz VS, de Andrade M, Therneau TM. Random-effects Cox proportional hazards model: General variance components methods for time-to-event data. Genet Epidemiol. 2005;28:97–109
  16. Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM. Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prev Med. 2006;30:371–377
  17. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;42:677–684
  18. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69:375–382
  19. Evans M, Fryzek JP, Elinder CG, et al. The natural history of chronic renal failure: Results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis. 2005;46:863–870
  20. National Kidney Foundation. DOQI Clinical Practice Guidelines for Hemodialysis Adequacy. Am J Kidney Dis. 1997;30(suppl 2):S15–S66
  21. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis. 2000;35(suppl 1):S1–S140
  22. Sehgal AR. Impact of quality improvement efforts on race and sex disparities in hemodialysis. JAMA. 2003;289:996–1000
  23. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. Causes of death in dialysis patients: Racial and gender differences. J Am Soc Nephrol. 1994;5:1231–1242
  24. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329:1001–1006
  25. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005;20:1880–1888
  26. Lacson E, Ikizler TA, Lazarus JM, Teng M, Hakim RM. Potential impact of nutritional intervention on ESRD hospitalization, death and treatment costs. J Ren Nutr. 2007;17:363–371
  27. Peters VJ, Clemons G, Augustine B. “Fistula First” as a CMS breakthrough initiative: Improving vascular access through collaboration. Nephrol Nurs J. 2005;32:686–687
  28. Lacson E, Lazarus JM, Himmelfarb J, Ikizler TA, Hakim RM. Balancing Fistula First with Catheters Last. Am J Kidney Dis. 2007;50:379–395
  29. Konner K. Should nephrologists be in charge?. Contrib Nephrol. 2005;149:121–130
  30. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  31. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125
  32. Cheng S, Coyne D. Vitamin D and outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2007;16:77–82
  33. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  34. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–1013
  35. National Kidney Foundation. II. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Adults. Am J Kidney Dis. 2006;47(suppl 1):S16–S85
  36. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis. 2005;45(suppl 3):S1–S153
  37. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  38. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  39. Port FK, Pisoni RL, Bragg-Gresham JL, et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif. 2004;22:175–180
  40. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med. 2006;145:512–519
  41. Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?. J Am Soc Nephrol. 2007;18:2377–2384
  42. Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: A 2-year multicenter, prospective, randomized study. J Am Soc Nephrol. 2007;18:2583–2591
  43. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69:560–564
  44. Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37:395–402
  45. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  46. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  47. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–1892
  48. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–1886
  49. Levin A. Understanding recent haemoglobin trials in CKD: Methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant. 2007;22:309–312

 Originally published online as doi:10.1053/j.ajkd.2008.07.031 on October 20, 2008.

PII: S0272-6386(08)01234-1

doi: 10.1053/j.ajkd.2008.07.031

American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 79-90 , January 2009

Article Tools

* Image Usage & Resolution